Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Distributing Is Not Licensing: PDL BioPharma Loses Patent, Royalty Battle With MedImmune

This article was originally published in The Pink Sheet Daily

Executive Summary

A California federal court rules that a PDL patent claim is invalid and that MedImmune did not have to pay royalties on sales by its ex-U.S. distributor Abbott; MedImmune may seek repayment of $280 million in royalties.

You may also be interested in...



Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter

AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.

Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter

AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.

Facet Says Yes To Abbott's $720 Million Buyout Offer

The antibody specialist said no to Biogen Idec in December and found a better offer of nearly $10 more a share.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel